Yoon YH, et al. - Researchers designed a prospective, double-blind, randomized clinical trial to evaluate the improvement in reflux symptom index (RSI) and reflux finding score (RFS) following treatment of laryngopharyngeal reflux disease (LPR) with three different regimens. For 3 months, one of the following regimens were prescribed to 100 patients with LPR: group A, ilaprazole 10 mg, once a day (QD), n = 29; group B, ilaprazole 10 mg, twice a day (BID), n = 27; and group C, ilaprazole 10 mg BID plus mosapride citrate 5 mg three times a day (TID), n = 44. As per total RFS and RSI scores, the 3 proton pump inhibitor (PPI) therapeutic strategies were similarly efficacious against LPR. Observations revealed improvements in specific endoscopic findings, such as vocal cord edema and diffuse laryngeal edema when a prokinetic was added. Moreover, for overweight or obese patients, the addition of a prokinetic to PPI therapy was particularly beneficial.